Literature DB >> 27787835

White Coat Hypertension: to Treat or Not to Treat?

Cesare Cuspidi1,2,3, Carla Sala4, Guido Grassi5,6, Giuseppe Mancia5.   

Abstract

Definition of white coat hypertension (WCH) traditionally relies on elevated office blood pressure (BP) during repeated visits concomitant with normal out-of-office BP values, as assessed by home and/or 24-h ambulatory BP monitoring measurements. Accumulating evidence focusing on the association of WCH with target organ damage and, more importantly, with cardiovascular events indicates that the risk conveyed by this condition is intermediate between normotension and sustained hypertension. This article will review a number of issues concerning WCH with particular emphasis on the following: (1) prevalence and clinical correlates, (2) association with target organ damage and cardiovascular events, (3) therapeutic interventions. Data will refer to the original WCH definition, based on out-of-office BP determined by 24-h ambulatory BP monitoring; at variance from home BP measurement, this approach rules out the potentially confounding effect of a clinically relevant abnormal BP phenotype such as isolated nocturnal hypertension.

Entities:  

Keywords:  Cardiovascular prognosis; Organ damage; Treatment; White coat hypertension

Mesh:

Year:  2016        PMID: 27787835     DOI: 10.1007/s11906-016-0687-9

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  41 in total

1.  Isolated clinic hypertension in a general population.

Authors:  Cesare Cuspidi; Gianfranco Parati
Journal:  J Hypertens       Date:  2006-03       Impact factor: 4.844

2.  How common is white coat hypertension?

Authors:  T G Pickering; G D James; C Boddie; G A Harshfield; S Blank; J H Laragh
Journal:  JAMA       Date:  1988-01-08       Impact factor: 56.272

3.  Comparison of demographic, clinical, and laboratory parameters between patients with sustained normotension, white coat hypertension, masked hypertension, and sustained hypertension.

Authors:  Baris Afsar
Journal:  J Cardiol       Date:  2013-01-05       Impact factor: 3.159

4.  Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: Data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] Study).

Authors:  R Sega; G Trocino; A Lanzarotti; S Carugo; G Cesana; R Schiavina; F Valagussa; M Bombelli; C Giannattasio; A Zanchetti; G Mancia
Journal:  Circulation       Date:  2001-09-18       Impact factor: 29.690

5.  Subclinical arterial and cardiac damage in white-coat and masked hypertension.

Authors:  Wiktoria Wojciechowska; Katarzyna Stolarz-Skrzypek; Agnieszka Olszanecka; Łukasz Klima; Jerzy Gąsowski; Tomasz Grodzicki; Kalina Kawecka-Jaszcz; Danuta Czarnecka
Journal:  Blood Press       Date:  2016-03-08       Impact factor: 2.835

6.  White-coat hypertension: a selection bias? Harvest Study Investigators. Hypertension and Ambulatory Recording Venetia Study.

Authors:  P Palatini; F Dorigatti; E Roman; P Giovinazzo; D Piccolo; G De Venuto; M Mattarei; E Cozzutti; S Gregori; P Mormino; A C Pessina
Journal:  J Hypertens       Date:  1998-07       Impact factor: 4.844

Review 7.  White-coat hypertension and cardiovascular events: a meta-analysis.

Authors:  Alexandros Briasoulis; Emmanuel Androulakis; Mohan Palla; Nikolaos Papageorgiou; Dimitris Tousoulis
Journal:  J Hypertens       Date:  2016-04       Impact factor: 4.844

8.  White coat hypertension is a cardiovascular risk factor: a 10-year follow-up study.

Authors:  P H Gustavsen; A Høegholm; L E Bang; K S Kristensen
Journal:  J Hum Hypertens       Date:  2003-12       Impact factor: 3.012

9.  Effect of long-term antihypertensive treatment on white-coat hypertension.

Authors:  Giuseppe Mancia; Rita Facchetti; Gianfranco Parati; Alberto Zanchetti
Journal:  Hypertension       Date:  2014-09-22       Impact factor: 10.190

10.  Does white coat hypertension require treatment over age 80?: Results of the hypertension in the very elderly trial ambulatory blood pressure side project.

Authors:  Christopher J Bulpitt; Nigel Beckett; Ruth Peters; Jan A Staessen; Ji-Guang Wang; Marius Comsa; Robert H Fagard; Dan Dumitrascu; Vesselka Gergova; Riitta L Antikainen; Elizabeth Cheek; Chakravarthi Rajkumar
Journal:  Hypertension       Date:  2012-11-19       Impact factor: 10.190

View more
  12 in total

1.  Diagnosis and management of white-coat hypertension in children and adolescents: A Midwest Pediatric Nephrology Consortium study.

Authors:  Yosuke Miyashita; Joseph T Flynn; Coral D Hanevold
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-07-23       Impact factor: 3.738

2.  Telemedicine in prenatal care.

Authors:  Hynek Heřman; Adéla Faridová; Ondřej Tefr; Sarah Farid; Noble Ayayee; Klára Trojanová; Jindřich Mareš; Petr Křepelka; Jiří Hanáček; Barbora Jalůvková; Ladislav Krofta; Jaroslav Feyereisl
Journal:  Cent Eur J Public Health       Date:  2022-06       Impact factor: 1.154

3.  The prevalence of masked hypertension and masked uncontrolled hypertension in relation to overweight and obesity in a nationwide registry in China.

Authors:  Jia-Hui Xia; Dong-Yan Zhang; Yuan-Yuan Kang; Qian-Hui Guo; Yi-Bang Cheng; Jian-Feng Huang; Qi-Fang Huang; Wei Zhang; Li-Juan Zhang; Yu Dou; Yan-Lun Su; Hua-Ling Liu; Mei-Sheng Zheng; Xin-Juan Xu; Jian-Jun Mu; Yan Li; Ji-Guang Wang
Journal:  Hypertens Res       Date:  2022-09-14       Impact factor: 5.528

4.  Self-Monitoring Home Blood Pressure in Community-Dwelling Older People: Age Differences in White-Coat and Masked Phenomena and Related Factors-The SONIC Study.

Authors:  Jinmei Tuo; Kayo Godai; Mai Kabayama; Yuya Akagi; Hiroshi Akasaka; Yoichi Takami; Yasushi Takeya; Koichi Yamamoto; Ken Sugimoto; Saori Yasumoto; Yukie Masui; Yasumichi Arai; Kazunori Ikebe; Yasuyuki Gondo; Tatsuro Ishizaki; Hiromi Rakugi; Kei Kamide
Journal:  Int J Hypertens       Date:  2022-04-30       Impact factor: 2.434

5.  Causal inference on electronic health records to assess blood pressure treatment targets: an application of the parametric g formula.

Authors:  Kipp W Johnson; Benjamin S Glicksberg; Rachel A Hodos; Khader Shameer; Joel T Dudley
Journal:  Pac Symp Biocomput       Date:  2018

Review 6.  Labile hypertension: a new disease or a variability phenomenon?

Authors:  Elias Sanidas; Charalampos Grassos; Dimitrios P Papadopoulos; Maria Velliou; Kostas Tsioufis; Marina Mantzourani; Despoina Perrea; Dimitrios Iliopoulos; John Barbetseas; Vasilios Papademetriou
Journal:  J Hum Hypertens       Date:  2019-01-15       Impact factor: 3.012

Review 7.  Diversity of and initiatives for hypertension management in Asia-Why we need the HOPE Asia Network.

Authors:  Kazuomi Kario; Yook-Chin Chia; Apichard Sukonthasarn; Yuda Turana; Jinho Shin; Chen-Huan Chen; Peera Buranakitjaroen; Jennifer Nailes; Satoshi Hoshide; Saulat Siddique; Jorge Sison; Arieska Ann Soenarta; Guru Prasad Sogunuru; Jam Chin Tay; Boon Wee Teo; Yu-Qing Zhang; Sungha Park; Huynh Van Minh; Naoko Tomitani; Tomoyuki Kabutoya; Narsingh Verma; Tzung-Dau Wang; Ji-Guang Wang
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-11-26       Impact factor: 3.738

8.  The impact of apelin and relaxin plasma levels in masked hypertension and white coat hypertension.

Authors:  Elias Sanidas; Kostas Tsakalis; Dimitrios P Papadopoulos; Kanella Zerva; Maria Velliou; Despoina Perrea; Marina Mantzourani; Dimitrios Iliopoulos; John Barbetseas
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-12-07       Impact factor: 3.738

9.  The differential diagnostic value of serum homocysteine for white coat hypertension.

Authors:  Shitian Guo; Hui Lin; Sunlei Pan; Xiaoya Zhai; Liping Meng
Journal:  Oncotarget       Date:  2017-09-18

10.  American Versus European Hypertension Guidelines: The Case of White Coat Hypertension.

Authors:  Cesare Cuspidi; Federico Paoletti; Marijana Tadic; Carla Sala; Raffaella Dell'Oro; Guido Grassi; Giuseppe Mancia
Journal:  Am J Hypertens       Date:  2020-07-18       Impact factor: 2.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.